Caplin Point laboratories strengthens board, reports strong half-year financials

Caplin Point Laboratories Limited announced impressive financial results for the half-year ended September 30, 2025, with total revenue reaching ₹1,098 Crores and profit after tax (PAT) at ₹311 Crores. This performance surpasses full-year revenues of FY21 and PAT of FY22, driven by new product launches and strong performance in emerging and US markets. Gross margin for H1 FY26 stood at 61.2%, and EBITDA margin at 38.3%.

The company also announced significant board changes. Mr. Ashok Partheeban and Mr. Vivek Partheeban have been appointed as additional directors and vice-chairmen, effective November 5, 2025. Concurrently, Mr. Vivek Partheeban relinquished his position as chief operating officer (COO) to assume his new board role. Dr. K. C. John has been appointed as an additional director (non-executive independent) for a five-year term, also effective November 5, 2025. These appointments are subject to shareholder approval.

Caplin Point continues its strategic growth initiatives, including an enhanced Capex budget of approximately ₹1,000 Crores for investment projects. The company aims to augment production capacities, widen its product range, and achieve backward integration. Its US market revenue recorded 27% growth year-on-year, reaching ₹221 Crores, supported by 42 ANDA approvals.